Free Trial

Mineralys Therapeutics (MLYS) Insider Trading & Ownership

Mineralys Therapeutics logo
$13.53 +0.32 (+2.42%)
Closing price 04:00 PM Eastern
Extended Trading
$13.92 +0.40 (+2.92%)
As of 07:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Mineralys Therapeutics (NASDAQ:MLYS) Insider Buying and Selling Activity

Current
Insider Ownership
Percentage
33.24%
Number Of
Insiders Buying
(Last 12 Months)
2
Amount Of
Insider Buying
(Last 12 Months)
$25.60 M
Number Of
Insiders Selling
(Last 12 Months)
4
Amount Of
Insider Selling
(Last 12 Months)
$11.57 M
Get MLYS Insider Trade Alerts

Want to know when executives and insiders are buying or selling Mineralys Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily.

MLYS Insider Buying and Selling by Quarter

Mineralys Therapeutics Insider and Congressional Trades History

Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/14/2025David Malcom RodmanInsiderSell11,366$14.53$165,147.98  
4/11/2025Adam Scott LevyCFOSell10,757$12.06$129,729.42  
4/11/2025Jon CongletonCEOSell15,319$12.19$186,738.61  
4/1/2025David Malcom RodmanInsiderSell55,771$15.76$878,950.96  
3/13/2025Ra Capital Management, L.P.DirectorBuy1,296,296$13.50$17,499,996.00  
3/13/2025Samsara Biocapital Gp, LlcMajor ShareholderBuy600,000$13.50$8,100,000.00  
1/13/2025Adam Scott LevyCFOSell10,757$9.10$97,888.70  
1/13/2025Jon CongletonCEOSell18,333$9.06$166,096.98  
11/6/2024David Malcom RodmanInsiderSell25,482$15.03$382,994.46  
10/11/2024Adam Scott LevyCFOSell10,757$13.57$145,972.49  
10/11/2024Jon CongletonCEOSell15,271$13.52$206,463.92  
7/24/2024Brian Taylor SlingsbyDirectorSell550,000$13.05$7,177,500.00  
7/16/2024David Malcom RodmanInsiderSell525$15.00$7,875.00  
7/11/2024Adam Scott LevyCFOSell10,757$13.14$141,346.98  
7/11/2024Jon CongletonCEOSell15,746$13.34$210,051.64  
6/14/2024Jon CongletonCEOSell16,229$12.52$203,187.08  
6/12/2024Jon CongletonCEOSell16,607$12.77$212,071.39  
6/11/2024Adam Scott LevyCFOSell96,815$12.94$1,252,786.10  
5/9/2024David Malcom RodmanInsiderSell100$15.00$1,500.00  
(Data available from 1/1/2013 forward)

MLYS Insider Trading Activity - Frequently Asked Questions

The list of insiders at Mineralys Therapeutics includes Adam Scott Levy, Brian Taylor Slingsby, David Malcom Rodman, Hbm Healthcare Investments (Ca, Jon Congleton, Ra Capital Management, L.P., and Samsara Biocapital Gp, Llc. Learn more on insiders at MLYS.

33.24% of Mineralys Therapeutics stock is owned by insiders. Learn more on MLYS's insider holdings.

The following insiders have purchased MLYS shares in the last 24 months: Jon Congleton ($105,557.50), Ra Capital Management, L.P. ($17,499,996.00), and Samsara Biocapital Gp, Llc ($15,599,992.50).

Insiders have purchased a total of 2,462,601 MLYS shares in the last 24 months for a total of $33,205,546.00 bought.

The following insiders have sold MLYS shares in the last 24 months: Adam Scott Levy ($1,767,723.69), Brian Taylor Slingsby ($7,177,500.00), David Malcom Rodman ($3,448,804.11), and Jon Congleton ($1,184,609.62).

Insiders have sold a total of 1,037,683 Mineralys Therapeutics shares in the last 24 months for a total of $13,578,637.42 sold.

Mineralys Therapeutics Key Executives



This page (NASDAQ:MLYS) was last updated on 4/23/2025 by MarketBeat.com Staff
From Our Partners